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ABSTRACT
Introduction: The purpose of this study was to
investigate the safety and efficacy of
transcorneal electrical stimulation (TES) in
patients suffering from retinal artery occlusion
(RAO).
Methods: Twelve patients with central and one
patient with branch RAO (age 25–84 years,
median 74 years) were enrolled in this
prospective, randomized, sham-controlled
study. RAO was diagnosed 10 days to 17
months prior to study participation. Patients
were treated with TES (5 ms positive followed by
5 ms negative biphasic pulses at 20 Hz; applied
with DTL electrodes) for 30 min once a week for
6 consecutive weeks. Patients were randomly
assigned to TES with 0 mA (sham, n = 3), 66%
(n = 5) or 150% (n = 5) of the patient’s
individual electrical phosphene threshold
(EPT) at 20 Hz. Best corrected visual acuity,
ophthalmology examination and EPT (at 3, 6, 9,
20, 40, 60, and 80 Hz) were determined at
baseline and at eight follow-up visits over
17 weeks. During four visits (week 1, 5, 9, and
17) kinetic and static visual fields as well as
full-field and multifocal electroretinography
were measured. The method of restricted
maximum likelihood (P\0.05, Tukey–Kramer)
was used to estimate the development of
parameters under treatment.
Results: TES was tolerated well; no ocular or
systemic adverse events were observed except
for foreign-body sensation after TES (n = 3).
During the study period the slopes of the
scotopic a-wave increased significantly (high-
intensity flash white 10 cd.s/m2; P = 0.03) in
the 150% treatment group. All other parameters
in all other groups remained statistically
unchanged.
Conclusions: Although TES was tolerated well,
statistically significant improvements were
found only for specific a-wave slopes. This
is in contradiction to previous smaller,
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uncontrolled reports. Further studies with larger
sample sizes and longer duration might,
however, show additional significant effects.
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INTRODUCTION
Retinal artery occlusion (RAO) causes sudden,
painless visual loss and leads to irreversible
profound retinal damage in the majority of
cases [1]. Two types of RAO are commonly
found: central RAO (CRAO) and branch RAO
(BRAO). CRAO usually results in a dramatic,
permanent decrease in visual function [1, 2].
BRAO leads to visual field defects corresponding
to the ischemic retinal areas, and if the
occlusion does not involve the fovea, visual
acuity may not be impaired at all [2].
CRAO is an ophthalmic emergency with
treatment often recommended to start as soon
as possible, as experimental data show that
CRAO lasting for approximately 240 min results
in massive, irreversible retinal damage [3]. Since
the first detailed description of CRAO in 1859
by von Graefe [4], various therapies have been
proposed for the acute phase of nonarteritic
CRAO and claimed to be beneficial for visual
outcome: anterior chamber paracentesis [5, 6];
ocular massage [7]; intravenous injection of
urokinase or plasminogen activator [8]; and also
local injection of plasminogen activator [9].
However, Fraser and Siriwardena [10] found
that treatments for acute nonarteritic CRAO
reported in the literature were of unproven
efficacy and concluded that there was currently
not enough evidence to determine which, if
any, interventions had beneficial effects.
Recently, studies have shown that
stimulation with weak electrical currents
could have positive effects on degenerative
ophthalmologic diseases such as retinitis
pigmentosa (RP) [11], nonarteritic anterior
ischemic optic neuropathy or traumatic optic
neuropathy [12], and also RAO [13–15]. The
mechanism for these positive effects has been
suggested to be a favorable regulation of
neurotropic factors; electrical stimulation
has been linked to the upregulation of
neurotrophins in the central and peripheral
nervous systems [16–18], whereas in animal
experiments, electrical stimulation has been
shown to be beneficial for the survival
of photoreceptors in Royal College of
Surgeon’s rats [19] promoting the survival of
photoreceptors and improving retinal function
in rhodopsin P347L transgenic rabbits [20],
rescuing ganglion cells after optic nerve injury
in Wistar rats [21, 22], and preserving retinal
cells after light-induced retinal damage in
Sprague–Dawley rats [23–25].
The neuroprotective effects of electrical
stimulation have been attributed to growth
factors, such as insulin-like growth factor-1
[21, 26], fibroblast growth factor-2 [27, 28],
ciliary neurotrophic factor [29, 30], and
brain-derived neurotrophic factor [21, 31]. Also,
an overexpression of neuroprotective genes, e.g.,
B cell lymphoma-2 gene [32], has been reported.
Moreover, electrical stimulation leads to reduced
expression of some tumor necrosis factor and
BAX genes; the latter are related to apoptosis
signaling in retinal cells [33].
Another possible mechanism for the positive
effects of electrical stimulation could be the
associated increase in chorioretinal blood
circulation, which has been demonstrated
recently [34].
Transcorneal electrical stimulation (TES) in
patients with nonarteritic anterior ischemic
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optic neuropathy and traumatic optic
neuropathy [12], longstanding RAO [13, 14]
and BRAO [15] has demonstrated positive
effects on visual acuity, visual field, and
multifocal electroretinography (mfERG) in
nonrandomized studies with a small number
of patients.
Our recently published favorable results for
TES in RP patients [11] inspired us to investigate
the efficacy of TES in patients suffering
from RAO in a prospective, randomized,
sham-controlled, partially blinded, and Good
Clinical Practice (GCP)-conforming study.
MATERIALS AND METHODS
Patients
Patients were recruited from the outpatient
clinic and electronic medical records of the
Centre for Ophthalmology, University of
Tu¨bingen, Germany. Inclusion criteria were
age [18 years and best corrected visual acuity
(BCVA) between light perception and 0.7
logMAR.
Exclusion criteria were the presence
of other ophthalmologic diseases, particularly
proliferative retinal diseases, such as
diabetic retinopathy, retinal or choroidal
neovascularization, exudative age-related
macular degeneration, silicone oil tamponade,
and severe general diseases. Giant cell arteritis
was ruled out by detailed history, normal
serum levels of C-reactive protein, and normal
age-adjusted blood sedimentation rate.
Study Design
The study was performed at the Centre for
Ophthalmology, University of Tu¨bingen,
Germany. The protocol was approved by the
local ethics committee. All procedures followed
were in accordance with the ethical standards of
the responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1975, as
revised in 2008. Informed consent was obtained
from all patients for being included in the
study.
The study was conducted according to the
standards of GCP, the European Union
Directive for Medical Devices, and the German
Medical Product Law. The trial was supervised
by STZ eyetrial, a clinical trial unit at the Centre
for Ophthalmology, University of Tu¨bingen,
which is a certified member of the European
Vision Institute, Clinical Research Network
(European Vision Institute Research Network,
Coimbra, Portugal). STZ eyetrial provided study
documents, performed regular monitoring
visits, and controlled all study documentation
including adverse events (AEs). All documents,
especially inclusion criteria and study logs, were
reviewed; all electronic case report form data
were monitored, and source data verification
was conducted according to the International
Conference on Harmonisation (Geneva,
Switzerland) and GCP guidelines.
Patients were seen at nine visits over a period
of 17 weeks: one baseline visit (visit 1), followed
by six consecutive weekly visits (visits 2–7)
including application of TES (dates varied by
±2 days) and two follow-up visits (visits 8 and
9), which occurred 2 weeks (visit 8) and
11 weeks (visit 9) after visit 7 (the last visit
varied by ±10 days).
After the screening visit, patients were
randomly assigned to TES with 0 mA (sham),
66% of the patient’s individual electrical
phosphene threshold (EPT) at 20 Hz (66%), or
150% of the patient’s individual EPT (150%) at
20 Hz.
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Patients and technicians who performed
static and kinetic perimetry, as well as full-
field ERG and mfERG, were blinded to the
treatment group for the entire study period.
The physicians who performed all other
examinations and TES were not blinded to
study treatment because they were responsible
for setting the stimulation parameters.
Clinical Examinations
At all nine visits, ophthalmologic examinations
were performed: BCVA assessment using a
Snellen projector (SCP-660, Nidek Inc.,
Freemont, CA, USA) at a viewing distance
of 6 m; retro-illuminated Early Treatment
Diabetic Retinopathy Study charts (ETDRS,
ETDRS Visual Acuity Tester, Steinbeis-
Transferzentrum, Tu¨bingen, Germany) at a
viewing distance of 2 m distance; for both
Snellen and ETDRS examinations, a viewing
distance of 1 m was used if the visual acuity at 2
and 6 m was immeasurable. Also performed
were slit-lamp biomicroscopy, fundus
examination, and Goldmann applanation
tonometry (AT 900, Haag-Streit, Wedel,
Germany). At visits 1, 2, 5, 8, and 9, static and
kinetic perimetry were recorded. Perimetry was
performed with an Octopus 900 perimeter
(Haag-Streit, Wedel, Germany); background
luminance was 10 cd/m2 using white-on-white
stimuli and a fast threshold strategy (German
Adaptive Thresholding Estimation) [35] up to
85 eccentricity. For kinetic perimetry, white
stimuli (Goldmann III4e with constant angular
velocity of 3/s) up to 90 eccentricity were
presented every 15. Isopter and scotoma areas
(in degrees2) were quantified using the
machine’s built-in software algorithm. As a
quality criterion for kinetic perimetry, the
blind spot was detected with at least five
stimuli (Goldmann I4e) at 2/s.
All patients underwent initial visual field
testing at the screening visit and once again at
visit 1. Generally, only the test at visit 1 was
recorded.
At visits 1, 5, 8, and 9, ERG and mfERG were
conducted according to the standards of
the International Society for Clinical
Electrophysiology of Vision (ISCEV) [36, 37].
ERG was recorded using an Espion E2
(Diagnosys LLC, Cambridge, UK) and a
ColorDome (Diagnosys LLC, Cambridge, UK).
The protocol consisted of six steps with
stimulus strengths from 0.01 to 10 cd.s/m2 and
4 ms duration (white 6500K). Three single-flash
stimuli were used under scotopic conditions
(stimulus strength 0.01 cd.s/m2; rod response),
3 cd.s/m2 (standard flash, combined rod-cone
response), and 10 cd.s/m2 (high-intensity flash)
as a scotopic protocol. A single flash stimulus
with 3 cd.s/m2 (single-flash cone response) and
a 30 Hz flicker were chosen as a photopic
protocol. The impedance level was \10 kX.
A wide-range band-pass filter (from 0.3 to
300 Hz) was applied using the machine’s built-
in algorithm. ERG potentials \5 lV were
excluded from the analysis.
To perform mfERG, a VerisTM-System
(Electro-Diagnostic Imaging Inc., Redwood
City, CA, USA; software version Veris Science
TM 5.1) and a 2100 screen (‘‘UHR21L,’’ Nortech
Imaging Technologies, Plymouth, MN, USA;
resolution 1,024 9 768) positioned 32 cm in
front of the patient were used. The stimulus
consisted of 61 scaled hexagonal elements
presented with alternating black (5 cd/m2) and
white (100 cd/m2) fields covering a central
visual field of 60 9 55. The built-in algorithm
allowed recordings between 10 and 100 Hz,
amplified by a factor of 200,000.
All electrophysiologic examinations and
electrical stimulation were performed using a
single-use sterile DTL electrode [38] (Diagnosys,
28 Ophthalmol Ther (2013) 2:25–39
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Liverpool, UK) and a gold-plated cup electrode
(LKC Technologies Inc., Gaithersburg, MD,
USA) as a counter electrode (Fig. 1).
Cornea and conjunctiva were anesthetized
with 0.4% oxybuprocaine hydrochloride
(Conjuncain EDO, Bausch & Lomb, Rochester,
NY, USA). Pupils were dilated with 0.5%
tropicamide (Mydriaticum Stulln, Stulln,
Germany).
Determination of EPT and TES
TES and assessment of EPT were performed
using a neurostimulator (Twister; Dr. Langer
GmbH, Waldkirch, Germany) and a single-use
sterile DTL-electrode (Fig. 1). A gold-plated cup
electrode was used as a counter electrode, and
fixed on the ipsilateral temple (Fig. 1). EPT was
determined at all nine visits over a range of
frequencies.
The threshold was defined as the minimal
electric current that elicited phosphene
perception anywhere in the visual field. An
alternative forced choice method was used for
verification. The neurostimulator was modified
by the manufacturer to limit current output to
10 mA with increments starting from 1 lA.
Impedance of the electrodes was tested each
time prior to stimulation and at various
intervals during stimulation using the
machine’s built-in algorithm; impedance did
not exceed 5 kX.
Measurements were performed in darkness
with a very dim indirect light produced by the
shielded computer screen. To avoid
dark adaptation, the light was switched on
periodically (ca. every 60–90 s) [39]. Full
darkness was necessary to allow perception of
the very subtle phosphenes. The threshold at
20 Hz was determined three times, and the
average was taken at each study visit for the
calculation of individual stimulation strength
according to the treatment group. TES was
applied with 10 ms rectangular biphasic
current pulses (5 ms positive, directly followed
by 5 ms negative) at 20 Hz for 30 min once a
week for 6 consecutive weeks.
Data Analysis
Statistical analyses were performed using the
JMP statistical software (version 8.02, SAS
Fig. 1 Transcorneal electrical stimulation was performed
using a a sterile single-use DTL electrode and b a
commercially-available neurostimulator programmed with
c biphasic current pulses of 10 ms duration (5 ms positive,
directly followed by 5 ms negative) at a frequency of 20 Hz
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Institute, Cary, NC, USA). ERG data analysis was
performed using previously described software
[40]; the slope of the initial part of the a-wave
was calculated and compared to evaluate
photoreceptor activity [41]. Intra-individual
differences were calculated for each
patient between baseline and follow-up visits.
A comparison between treatment groups was
then performed using the method of restricted
maximum likelihood (REML) to estimate the
development of parameters under treatment
for each group. To compare groups, the
Tukey–Kramer post hoc test analysis was
applied with a significance level of P\0.05.
RESULTS
Thirteen patients with nonarteritic RAO were
enrolled (12 patients with CRAO and one patient
with BRAO, age range 25–84 years, median
74 years). In total, 20 patients were screened for
study participation and seven patients were
excluded from the study because they were not
able to deliver repeatable results in the visual field
examination due to poor fixation. RAO was
diagnosed 10 days to 17 months (median
11 months) prior to inclusion. Table 1 shows
detailed characteristics for all patients. The
numbers of patients assigned to the treatment
groups were: 0 mA TES (sham), n = 3; 66% of the
patients’ individual EPT at 20 Hz (60%), n = 5,
and 150% of the patients’ individual EPT at 20 Hz
(150%), n = 5.
All 13 patients completed the entire study.
TES using DTL-electrodes was well tolerated, as
reported previously [11, 39]. No ocular or
systemic AEs were observed, except for foreign-
body sensation after TES (n = 3).
All raw data and REML values are listed in
Table 2; excerpts follow in this section. At the
beginning, three patients reported phosphenes
only at some of the tested frequencies (20 and
40 Hz) despite stimulation currents up to 4 mA;
a level at which unpleasant sensations, such as a
twitch in the eyelid, were reported. In the
course of the study in two of these patients,
determination of EPT was possible at all tested
frequencies, whereas in one patient phosphenes
could only be evoked at 20 Hz at the end of the
study.
At all visits and in all patients, the lowest EPT
was found at 20 Hz. EPT (mean ± standard
deviation [SD]) at baseline was 0.97 ± 1.06 mA
at 20 Hz, 1.43 ± 1.36 mA at 40 Hz, 1.83 ±
1.51 mA at 60 Hz, 1.63 ± 1.42 mA at 80 Hz,
1.82 ± 1.50 mA at 3 Hz, 1.59 ± 1.36 mA at
6 Hz, and at 1.82 ± 1.50 mA 9 Hz. The
stimulation current ranged from 0.1 to 1.75 mA.
No statistically significant differences were
detected in visual field parameters (Table 2).
The mean defect, the mean sensitivity in static
visual field, and the area of kinetic visual field
did not differ significantly between the groups;
calculation of the changes in the area of the
kinetic visual field in the 150% treatment group
failed because the visual field was not
recordable in four patients at baseline
(Table 2). However, in some of the treated
patients, an enlargement of visual field
area was observed. Figure 2 shows fundus
photographs and the development of visual
field area in two selected patients in the 150%
treatment group. RAO was diagnosed in the first
of these patients at 7 months and in the second
of these patients at 6 months before study
enrollment.
During study visits no significant differences
were observed between the groups for
amplitudes and implicit times in the ERG
measurements under dark- or light-adapted
conditions (Table 2). There were, however,
statistically significant changes (P = 0.03) in
the a-wave slope of the high-intensity flash
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(10 cd.s/m2) under scotopic conditions with
increased values in the follow-up as compared
to baseline in the 150% treatment group with
mean ± standard error (SE) of 0.46 ± 0.7 lV/ms,
and decreased values in the 66% and
sham treatment groups of -2.1 ± 0.7 and
-1.74 ± 0.9 lV/ms, respectively.
DISCUSSION
Recently, studies with TES in humans have
shown that TES is safe and can exhibit positive
effects in patients with degenerative retinal
diseases [11–15]. In particular, a sham-
controlled pilot study in RP showed some
Fig. 2 Fundus photographs and development of visual
ﬁeld (VF) area in two selected patients from the group
treated with 150% of the individual electric phosphene
threshold at 20 Hz. In the treated patients, an enlargement
of VF area was observed, but statistical signiﬁcance was not
reached. Retinal artery occlusion was diagnosed in patient
1 (left) at approximately 7 months and in patient 2 (right)
at approximately 6 months prior to study enrollment.
LE right eye, RE right eye
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significant effects after only 6 weeks of TES
treatment [11].
In 2007, Inomata et al. [13] published a case
description of three patients with longstanding
RAO. Patients were treated with TES once a
month for a period of 3 months (stimulation
current up to 1.1 mA, 20 Hz biphasic pulses,
30 min, contact lens electrode). After treatment
the authors noted an improvement in visual
acuity of [0.2 logMAR in two cases and an
enlargement of the visual field in all three cases.
In 2010, Robles-Camarillo et al. [14]
investigated the effects of TES on low vision in
patients with CRAO. In the 2-month study,
nine patients were split into three groups:
control, TES treatment for 45 min twice per
month, and TES treatment for 45 min once per
week. TES was applied with contact lens
electrodes, although stimulation parameters
were not given in this publication. The group’s
results showed an improvement in visual acuity
and increased responses of the a- and b-wave in
the ERG data in all stimulated patients.
More recently, Oono et al. [15] in
2011 described an improvement in mfERG
responses in five patients with BRAO. A single
TES treatment was delivered using contact lens
electrodes; the current strength ranged between
0.5 and 0.9 mA with biphasic pulses at 20 Hz
while the duration of each session was 30 min.
To the authors’ knowledge, the present study
is the first randomized, sham-controlled, and
partially blinded study to investigate TES as a
potential treatment in patients with RAO. The
specific stimulation parameter was chosen due
to the fact that the lowest EPT was observed at
20 Hz. This trough for EPT at 20 Hz was also
found in healthy subjects, and patients with
other retinal diseases, such as RP, nonarteritic
anterior ischemic optic neuropathy, Stargardt’s
disease, and primary open-angle glaucoma
[42].
The stimulation current, calculated from the
individual EPT at 20 Hz, ranged in the present
study from 0.10 to 1.75 mA. In their studies
with RAO patients, Inomata et al. [13] and
Oono et al. [15] used stimulation currents
ranging from 0.50 to 1.10 mA. These values
are, remarkably, comparable to the values used
in the present study, despite significant
differences in techniques. The stimulation
time of 30 min in the present study was based
on that used in previous studies [11–13, 15]. The
frequency of application in the present study
(once weekly in 6 consecutive weeks) was
selected on the basis that more intensive
stimulation (vs. the three-times monthly TES
treatment used by Inomata et al. [13]) could
potentially have more positive effects.
In the 150% treatment group, a statistically
significant increase in the scotopic a-wave slope
was detected. As the a-wave slope is regarded
as the electrophysiologic representation of
the phototransduction process by the
photoreceptors [43–46], these results indicate
an improvement in photoreceptor activity
during TES treatment. All other tested
parameters failed to show statistically
significant improvements. A failure to reach
statistical significance may have been due to the
very small sample size, with only three to five
patients in each group. It may, however, also
have been due to the short study period of only
six stimulation sessions in an attempt to treat
very profound retinal damage; such damage
usually has a very poor prognosis. In contrast to
this, in the present study with 24 RP patients
[11], significant improvements were found in
clinically relevant parameters, such as visual
field area and scotopic b-wave amplitude, under
the same study parameters, but had the chance
to examine a considerably larger study
population. Statistical significance would not
have been reached with smaller sample sizes as
36 Ophthalmol Ther (2013) 2:25–39
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recalculations of the present data have shown.
In the present study subgroup analysis of data
was not done because the groups were small,
although an improvement in two longstanding
cases is in accordance with previous reports by
Inomata et al. [13]. It should be emphasized
here that the cases included in the Inomata
et al. [13] study and all other previous studies
mentioned [14, 15] were based on uncontrolled
series with a limited strength of evidence. The
possibility that the present findings may have
been biased by a potential imbalance in the
study groups, such as differing extent and
severity of retinal damage, and inconsistent
timing of TES treatment, cannot be completely
eliminated.
As a statistically significant clinical effect
from the present data could not be shown, TES
cannot be currently recommended as a
treatment for CRAO or BRAO. Hayreh and
Zimmerman [1] reported that without any
treatment, an improvement in visual acuity
and visual field is observed in only 6% of eyes
with nonarteritic CRAO. However, the visual
outcome in CRAO patients using existing
treatments is unsatisfactory; various studies of
new treatments for CRAO have shown no
significant differences in the visual outcome
between treated and untreated patients [6,
47–49]. Considering the lack of scientifically
justifiable treatment options for BRAO and
CRAO, and taking into account the limitations
of the present study (short duration, small
sample size) and the statistically significant
improvement detected in a-wave slopes,
further investigation is warranted to explore
the potential of TES for these conditions. Any
further studies on the therapeutic value of TES
should retain the stringent use of a sham
control, as used in the present study, and
maintain study groups as homogeneously as
possible. It may be possible that the initiation of
treatment with TES very shortly after the onset
of RAO might have a clearer effect on the course
of the disease.
In conclusion, TES provides several potential
advantages over intravitreal injections or
surgical interventions, e.g., minimal
invasiveness. Furthermore, TES most probably
generates low treatment costs, and the
simplicity of the concept also means
considerable ease of use for both the examiner
and the patient. Therefore, it is conceivable that
patients may be allowed a stimulation device at
home.
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